

## References

1. Amosova EN. Novie vosmozhnosti snizhenia cardiovascularnogo riska u bolnich s arterialnoj gipertensiej. *Ukrainskyi kardiologichnyi zhurnal – Ukr J Cardiol* 2006;1:19–25 (in Russ).
2. Batushkin V, Malchevsky V, Gema A, Malchevska T. Sposib diagnostiki porushennja funkcionalnogo stanu endoteliju peryferichnyh arteriy v osib na gostriy koronarniy sindrom. Declarasiyniy patent na korisnu model 7425 7 A61B8/06 15.06.2005. *Biuletyn* 6:4–5(in Ukr.).
3. Batushkin V. Vpliv visokih dos dirotona na osoblivosti perebigu GIM bes subsa Q ta suputnoju gipertonichnoju hvoroboju v salezhnosti vid stupenju porushennja funktsii endoteliju ta trombositarного gemostasa. *Ukrainskyi medychnyi chasopys – Ukr Med J* 2005;4:42–47(in Ukr).
4. Sledzevskaia I., Babii L, Stroganova N, Savitskii S, Homenko J, Kisilevich L. Kompensatornie factory, opredelajuschie funkcionalnoe sostojanie serdsa u bolnih perenessih infarct miokarda (dvuhletnee nabludenie). Materialy XIV Nasionalnogo kongresu kardiologiv Ukrainy. *Ukrainskyi kardiologichnyi zhurnal – Ukr J Cardiol* 2013;4:169 (in Russ).
5. ACC/AHA Guidelines for the Management of High Blood Pressure in Adults: Report From the Panel Members Appointed to the Eighth Joint National Committee (JNC 8) *JAMA* 2013; doi:10.1001/jama.2013.284427.
6. Borghi C, Ambrosioni E. Survival of Myocardial Infarction Long-term Evaluation-2 Working Party. Double-blind comparison between zofenopril and lisinopril in patients with acute myocardial infarction: results of the Survival of Myocardial Infarction Long-term Evaluation-2 (SMILE-2) study. *Am Heart J* 2003;145(1):80–7.
7. Borghi C, Ambrosioni E. Survival of Myocardial Infarction Long-term Evaluation Study Group. Effects of zofenopril on myocardial ischemia in post-myocardial infarction patients with preserved left ventricular function: the Survival of Myocardial Infarction Long-term Evaluation (SMILE)-ISCHEMIA study. *Am Heart J* 2007;153(3):445.e7–14.
8. Buikema H, Monnick SH, Tio RA. Comparison of zofenopril and lisinopril to study the role of the sulfhydryl-group in improvement of endothelial dysfunction with ACE-inhibitors in experimental heart failure. *Br J Pharmacol* 2000;130(8):1999–2007.
9. Cominacini L, Pasini A, Garbin U. Zofenopril inhibits the expression of adhesion molecules on endothelial cells by reducing reactive oxygen species. *Am J Hypertens* 2002;15:891–5.
10. Frascarelli S, Ghelardoni S, Ronca-Testoni S, Zucchi R. Cardioprotective effect of zofenopril in perfused rat heart subjected to ischemia and reperfusion. *J Cardiovasc Pharmacol* 2004;Feb;43(2):294–9.
11. Heeneman S, Sluimer JC, Daemen MJ. Angiotensin-converting enzyme and vascular remodeling. *Circ Res* 2007;101:441–54.
12. Evangelista S, Manzini S. Antioxidant and cardioprotective properties of the sulphhydryl angiotensin-converting enzyme inhibitor zofenopril. *J Int Med Res* 2005;33(1):42–54.
13. Lacourciere Y, Provencher P. Comparative effects of zofenopril and hydrochlorothiazide on office and ambulatory blood pressures in mild to moderate essential hypertension. *Br J Clin Pharmacol* 1989;27(3):371–6.

14. Mak IT, Freedman AM, Dickens BF, Weglicki WB. Protective effects of sulfhydryl-containing angiotensin converting enzyme inhibitors against free radical injury in endothelial cells. *Biochem Pharmacol* 1990;40(9):2169–75.
15. Malacco E, Piazza S, Omboni S. Zofenopril versus Lisinopril in the Treatment of Essential Hypertension in Elderly Patients: A Randomised, Double-Blind, Multicentre Study. *Clin Drug Investig* 2005;25(3):175–182.
16. Napoli C, Sica V, de Nigris F. Sulfhydryl angiotensin-converting enzyme inhibition induces sustained reduction of systemic oxidative stress and improves the nitric oxide pathway in patients with essential hypertension. *Am Heart J* 2004;148(1):e5.
17. Pasini AF, Garbin U, Nava MC. Effect of sulfhydryl and non-sulfhydryl angiotensin-converting enzyme inhibitors on endothelial function in essential hypertensive patients. *Am J Hypertens* 2007;Apr;20(4):443–50.
18. Scribner AW, Loscalzo J, Napoli C. The effect of angiotensin-converting enzyme inhibition on endothelial function and oxidant stress. *Eur J Pharmacol.* 2003 15;482(1–3):95–9.
19. Steg PhG, James SK, Dan Atar. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation The Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC). *Eur Heart J* 2012;33: 2569–2619
20. van Gilst WH, Scholtens E, de Graeff PA. Differential influences of angiotensin converting-enzyme inhibitors on the coronary circulation. *Circulation* 1988;77(6 Pt 2):I24–9.